Clinical trials: Rituximab, completed
Purpura, Thrombocytopenic, Idiopathic
The PROLONG Trial - Rituximab Maintenance Therapy in ITP
This study is a two phase study that aims to evaluate if low-dose Rituximab maintenance therapy may prolong the the effect of Rituximab in immune thrombocytopenia.
- Trial name
- NCT03010202
- Testing
- Dexamethasone, Rituximab
- Where
- Norway
- Volunteers
- 136 people
- Sponsor
- Ostfold Hospital Trust
Lymphocytic Leukemia, Mantle Cell Lymphoma
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
The purpose of this research is to evaluate the use of Rituximab in combination with Revlimid in the treatment of refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT00609869
- Testing
- Lenalidomide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as carmustine, etoposide, cytarabine, and melphalan work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00244946
- Testing
- therapeutic autologous lymphocytes, carmustine, cytarabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Follicular Lymphoma
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this disease, with AT-101, an experimental drug.
- Trial name
- NCT00440388
- Testing
- AT-101, Rituximab
- Where
- 28 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ascenta Therapeutics
Follicular Lymphoma
Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma
Patients with non-curable disseminated follicular lymphoma receive local radiotherapy targeting single lymph nodes and injection of low-dose rituximab (anti-CD20) and autologous dendritic cells.
- Trial name
- Lymvac-1 (NCT01926639)
- Testing
- Radiotherapy, rituximab and DC
- Where
- Norway
- Volunteers
- 14 people
- Sponsor
- Oslo University Hospital
Lymphoma
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00784927
- Testing
- rituximab, cyclophosphamide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Lymphoma
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00080886
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Nebraska
Diffuse, Large B-Cell, Lymphoma
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
The use of R-CHOP, given every two weeks, will be associated with improvements in response rate, and progression-free survival, when compared to R-CHOP given every three weeks.
- Trial name
- NCT00599170
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Southern California
Rheumatoid Arthritis, Spondyloarthritis
Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
Background The risk for hospitalized infection (i.e. infection leading to hospitalization) in patients with inflammatory arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis
- Trial name
- NCT03496831
- Testing
- Biologic Agents
- Volunteers
- 7,500 people
- Sponsor
- Simon Krabbe
Non-Hodgkin's Lymphoma
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has…
- Trial name
- NCT00517049
- Testing
- PRO95780, rituximab
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
The primary objective of this study is to assess the effect of treatment with bendamustine on cardiac repolarization as reflected by the rate-corrected QT interval by the Fridericia method (QTcF).
- Trial name
- NCT01073163
- Testing
- Bendamustine, Rituximab
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 54 people
- Sponsor
- Cephalon
Burkitt Lymphoma, B-ALL
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
The study was set up to assess the efficacy and tolerability of a chemotherapy-immunotherapy combination programme originally introduced by GMALL (the German cooperative group for adult acute lymphoblastic leukemia)in 2002, to…
- Trial name
- NCT01290120
- Testing
- Chemotherapy-Rituximab combination
- Where
- 12 sites in Italy
- Volunteers
- 182 people
- Sponsor
- Northern Italy Leukemia Group
Lymphoma
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00031642
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Nebraska
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of carfilzomib when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with diffuse large B-cell lymphoma.
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02073097
- Testing
- Carfilzomib, Rituximab, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Diffuse Large B-Cell Lymphoma
Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)
The purpose is to test whether dose densified chemoimmunotherapy followed by central nervous system (CNS) prophylaxis for young high risk diffuse large B-cell lymphoma (DLBCL) patients is feasible and could improve time to…
- Trial name
- CRY-04 (NCT01502982)
- Testing
- R-CHOEP14x6+HD-AraC+HD-Mtx
- Where
- 4 sites in Denmark, Finland and 2 more
- Volunteers
- 160 people
- Sponsor
- Nordic Lymphoma Group
Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
Phase I/II trial to study the effectiveness of combining yttrium Y 90 ibritumomab tiuxetan with rituximab in treating patients who have localized or recurrent lymphoproliferative disorder after an organ transplant.
- Conditions
- Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage III Adult Burkitt Lymphoma
- Trial name
- NCT00064246
- Testing
- rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
This observational, prospective, multicenter study will evaluate the efficacy and safety of MabThera/Rituxan in participants with active rheumatoid arthritis and an inadequate response or intolerance to one anti-TNF therapy.
- Trial name
- NCT01641952
- Testing
- Rituximab
- Where
- Romania
- Volunteers
- 505 people
- Sponsor
- Hoffmann-La Roche
PTLD, Posttransplant Lymphoproliferative Disorder
Risk Stratified Sequential Treatment for CD20-positive PTLD
This phase-II trial will investigate the efficacy, safety and the tolerability of a sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of R-CHOP chemotherapy in patients with CD20+…
- Trial name
- PTLD-1/3 (NCT00590447)
- Testing
- rituximab monotherapy, sequential R-CHOP
- Where
- 7 sites in Australia, Belgium and 5 more
- Volunteers
- 152 people
- Sponsor
- Charite University, Berlin, Germany
Follicular Lymphoma
Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon
This is a non-comparative, prospective, non-randomized single centre phase II clinical trial of Rituximab and alpha interferon immunotherapy following autologous stem cell transplant in patients with relapsed follicular lymphoma…
- Trial name
- NCT03069248
- Testing
- Rituximab, Alpha Interferon
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Sunnybrook Health Sciences Centre
Kidney Transplant
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
The purpose of this study is to examine the safety and efficacy of IVIG in combination with Rituximab to lower the level of HLA-sensitive antibodies and block their ability to attack a transplanted organ in patients who are…
- Trial name
- NCT00642655
- Testing
- IVIG and Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.